Klinikum Mutterhaus der Borromaeerinnen gGmbH — Clinical Trial Site

44 Registered trials

22 Currently recruiting

Organisation

Klinikum Mutterhaus der Borromaeerinnen gGmbH

Location

Trier, Germany

Identifier

ORG-100023890

Address

Feldstrasse 16, Innenstadt, 54290, Germany

Departments

Abt. für Innere Medizin
Abteilung für Innere Medizin I (Onkologie)
Apotheke
Darmkrebszentrum
Gynaekologie
Gynaekologie und Geburtshilfe
Gynäkolgie
Gynäkologie
Gynäkologischen Krebszentrums
Gynecology and Obstetrics
Hämatologie/Onkologie
Hemato-Oncology
Hematology
Hematology/Oncology
I. Medizinische Klinik
Innere Medizin
Innere Medizin 1
Innere Medizin I
Innere Medizin I Hämato-Onkologie, Infektiologie, Gastroenterologie
Inneren Medizin 1; Hämatologie und Onkologie
Internal Medicine
Internistische Onkologie
Klinik für Gynäkologie
Klinikum Mutterhaus der Borromäerinnen - Innere Medizin 1
Klinikum Mutterhaus der Borromäerinnen gGmbH
Krankenanstalt, Med. Abteilung I
Medizinische Klinik
MVZ Strahlentherapie
N/A
NA
Onkologisches Zentrum

Clinical trials at this site (44)

Search interface

PREFer Recruiting

2024-520138-31-00 Early-stage favorable classic Hodgkin lymphoma 4 2026-06-01
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec… Recruiting

2025-520582-51-00 Hormone receptor positive breast cancer 5 2025-10-17
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
TYPER Recruiting

2024-520290-12-00 Hormone receptor–positive (HRpos)/human epidermal growt 6 2025-11-04
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici… Recruiting

2024-519929-38-00 Metastatic Colorectal Cancer without liver metastases 4 2025-10-27
A Study to Learn About a Study Medicine Called Ibuzatrelvir in People With Coronavirus Disease 2019 (COVID-19) and a Severely Compromised Im… Recruiting

2024-517671-21-00 Coronavirus Disease 2019 (COVID-19) 5 2025-09-30
A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting

2024-519331-42-00 pMMR endometrial carcinoma 5 2025-08-22
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting

2023-508787-29-00 Triple-negative early breast cancer with low risk for r 4 2024-10-10
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting

2022-501810-77-00 Relapsed or Refractory Marginal Zone Lymphoma 5 2023-09-01
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli… Recruiting

2024-512953-26-00 intermediate-stage hepatocellular carcinoma 5 2021-07-06
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Early-Stage Unfavorable Classical Hodgkin Lymphoma 4 2024-05-15
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15